The Role of Immune Checkpoint Inhibitors in Bladder Cancer

Co-Host: Robert Svatek, MD At the conclusion of these activities, participants will be able to: 1. Recognize both historic and newer immunotherapy options in the treatment of bladder cancer. 2. Describe the mechanism of action of immunotherapy regimens. 3. Identify and manage the adverse events related to these agents. CME Available: auau.auanet.org/node/26071 This educational series is supported by independent educational grants from: Amgen Astellas AstraZeneca Bristol-Myers Squibb Genomic Health Merck Pfizer, Inc. Sanofi Genzyme UroGen Pharma